Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Paratek Pharmaceuticals Inc    PRTK

PARATEK PHARMACEUTICALS INC (PRTK)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/11/2018 06/12/2018 06/13/2018 06/14/2018 06/15/2018 Date
10.9(c) 10.7(c) 10.55(c) 10.85(c) 11.05(c) Last
346 077 281 668 286 758 399 943 623 632 Volume
0.00% -1.83% -1.40% +2.84% +1.84% Change
More quotes
Financials (USD)
Sales 2018 15,3 M
EBIT 2018 -96,1 M
Net income 2018 -105 M
Finance 2018 169 M
Yield 2018 -
Sales 2019 44,9 M
EBIT 2019 -88,7 M
Net income 2019 -97,9 M
Debt 2019 12,0 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 11,8x
EV / Sales2019 8,05x
Capitalization 349 M
More Financials
Company
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry.Its products include Omadacycline and Sarecycline, which are used for the treatment of serious community-acquired bacterial infections, including community-acquired... 
More about the company
Surperformance© ratings of Paratek Pharmaceuticals In
Trading Rating : Investor Rating :
More Ratings
Latest news on PARATEK PHARMACEUTICALS IN
06/13PARATEK PHARMACEUTICALS : Presents New Analysis from Combined Phase 3 Skin Infec..
AQ
06/12PARATEK PHARMACEUTICALS : Presents New Analysis from Combined Phase 3 Skin Infec..
AQ
06/11Paratek Presents New Analysis from Combined Phase 3 Skin Infection Studies Hi..
GL
06/08PARATEK PHARMACEUTICALS : Demonstrates Breadth of Omadacycline Clinical and Micr..
AQ
06/07Paratek Demonstrates Breadth of Omadacycline Clinical and Microbiological Dat..
GL
06/01Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GL
05/23PARATEK PHARMACEUTICALS : Presents New Analysis Highlighting Efficacy of Omadacy..
AQ
05/22PARATEK PHARMACEUTICALS : Presents New Analysis Highlighting Efficacy of Omadacy..
AQ
05/15PARATEK PHARMACEUTICALS : Reports First Quarter 2018 Financial Results
AQ
05/09PARATEK : 1Q Earnings Snapshot
AQ
More news
Sector news : Bio Therapeutic Drugs
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
06/06Drugmaker Lundbeck to settle U.S. charity probe for $52.6 million
RE
06/01Lilly, Incyte Get FDA OK for Lower-Dose Rheumatoid Arthritis Drug
DJ
05/30Gap in regulating biotech drug copies prompts WHO to step in
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/15Paratek Pharmaceuticals $PRTK Given a $50.00 Price Target by Cantor Fitzgeral.. 
06/11Get the latest news and updates for $CAMP $PRTK $TSRX $VREX $UTMD automatical.. 
06/10Brokerages Set Paratek Pharmaceuticals Inc $PRTK Target Price at $45.00  
05/22Paratek $PRTK Presents New Analysis Highlighting Efficacy of Omadacycline in .. 
05/21Equities Analysts Issue Forecasts for Paratek Pharmaceuticals, Inc.’s Q2 2018.. 
More tweets
Qtime:42
News from SeekingAlpha
05/15Tracking Seth Klarman's Baupost Group Holdings - Q1 2018 Update 
05/13ACHAOGEN : Explicating The Prospects Of C-Scape 
05/09Paratek Pharmaceuticals' (PRTK) CEO Michael Bigham on Q1 2018 Results - Earni.. 
05/09Paratek up 1% on Q1 result 
05/09Paratek Pharmaceuticals EPS in-line 
Chart PARATEK PHARMACEUTICALS IN
Duration : Period :
Paratek Pharmaceuticals In Technical Analysis Chart | PRTK | US6993743029 | 4-Traders
Technical analysis trends PARATEK PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Average target price 36,9 $
Spread / Average Target 234%
EPS Revisions
Managers
NameTitle
Michael F. Bigham Chairman & Chief Executive Officer
Evan Loh President, COO, Director & Chief Medical Officer
Douglas W. Pagán Chief Financial & Accounting Officer
Paul McGovern Vice President-Clinical & Medical Affairs
Thomas John Dietz Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PARATEK PHARMACEUTICALS INC-38.27%349
GILEAD SCIENCES-0.68%91 317
VERTEX PHARMACEUTICALS3.42%39 504
REGENERON PHARMACEUTICALS-16.04%33 406
NEUROCRINE BIOSCIENCES, INC.31.87%9 198
GENMAB-6.67%9 197